Showing results (451-460 of 552) with videos related to
Sort By:
Pageof 56
JAMA Dermatology|October 1, 2020
Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical TrialKristian Reich, Kenji Kabashima, Ketty Peris, et al.Dermatology and Therapy|June 17, 2026
A Durability Index for Atopic Dermatitis: Indirect Comparison of Lebrikizumab, Dupilumab, and Tralokinumab in Maintaining Efficacy Under Variable Treatment AdherenceJonathan I Silverberg, Alan D Irvine, Peter Foley, et al.The Journal of Investigative Dermatology|June 29, 2019
IL-4Rα Blockade by Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Atopic DermatitisChris Callewaert, Teruaki Nakatsuji, Rob Knight, et al.Journal of the American Academy of Dermatology|March 13, 2025
Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with Chronic Hand Eczema: Results of the phase 3 open-label extension DELTA 3 trial following the DELTA 1 and 2 trialsMelinda Gooderham, Sonja Molin, Robert Bissonnette, et al.Dermatitis : Contact, Atopic, Occupational, Drug|May 10, 2021
North American Contact Dermatitis Group Patch Test Results: 2017-2018Joel G DeKoven, Jonathan I Silverberg, Erin M Warshaw, et al.Dermatology and Therapy|June 2, 2025
Rapid Itch Improvement and Skin Clearance with Upadacitinib Versus Placebo (Measure Up 1 and Measure Up 2) and Versus Dupilumab (Heads Up): Results from Three Phase 3 Clinical Trials in Patients with Moderate-to-Severe Atopic DermatitisEric L Simpson, Jonathan I Silverberg, Vimal H Prajapati, et al.Journal of Drugs in Dermatology : JDD|August 20, 2019
Efficacy of Dupilumab in Different Racial Subgroups of Adults With Moderate-to-Severe Atopic Dermatitis in Three Randomized, Placebo-Controlled Phase 3 TrialsAndrew F. Alexis, Marta Rendon, Jonathan I. Silverberg, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|June 19, 2023
Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND studyKristian Reich, Jonathan I Silverberg, Kim A Papp, et al.American Journal of Clinical Dermatology|May 9, 2019
Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled AnalysisLawrence F Eichenfield, Thomas Bieber, Lisa A Beck, et al.Contact Dermatitis|April 12, 2021
Patch testing with sodium disulfite: North American Contact Dermatitis Group experience, 2017 to 2018Erin M Warshaw, Michele Buonomo, Joel G DeKoven, et al.Pageof 56